![]() |
|
|
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin
Received May 9, 2003; accepted May 30, 2003
| Abstract |
|---|
|
|
|---|
The AHR has been shown to play an important role in normal development
(McDonnell et al., 1996
;
Schmidt et al., 1996
).
Although viable, AHR knockout mice display a slower growth rate, decreased
fertility, and a reduced liver size. These phenotypes seem to be related to
the fact that adult AHR null mice have an altered vascular architecture
(Lahvis et al., 2000
). The
developmental abnormalities in AHR-null animals indicate that this receptor is
required during development and that AHR may be activated by an endogenous
ligand in the course of normal development.
Our hypothesis is that the physiological role of the AHR is to regulate the metabolism of endogenously generated compounds that may be deleterious to the cell. The goal of this study was to identify enzymes that are involved in the production of AHR agonists. By identifying components of this pathway, we may ultimately identify the small molecule ligands that are important during development.
| Materials and Methods |
|---|
|
|
|---|
-ketoglutarate, oxaloacetate,
indole-3-acetate,
-naphthoflavone (BNF), bilirubin, and hemin were of
the highest purity available and were obtained from Sigma-Aldrich. Dimethyl
sulfoxide (DMSO) was the solvent for BNF,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and hemin. Ethanol was
the solvent for I3P, HPP, and indole-3-acetate stock solutions.
Cell Lines, Growth Conditions, and Plasmids. All cell lines were
grown in Dulbecco's modified Eagle's medium with high glucose (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate,
1 mM L-glutamine, minimal essential medium nonessential amino acids
(Invitrogen), and 10 mM HEPES, pH 7.5. Cultures were maintained at 7.5%
CO2 in a humidified atmosphere at 37°C. Activation of the AHR
was monitored using the 101L cell line. This reporter cell line is a
derivative of human HepG2 cells and contains a stably integrated luciferase
reporter gene driven by the DREs found within the CYP1A1 promoter
(Postlind et al., 1993
). All
reporter gene assays were carried out 15 to 20 h after treatment of the cells
with extracts or purified compounds. To identify the fractions that activated
AHR signaling from the various protein purification steps, aliquots of each
fraction were applied to PD-10 desalting columns to exchange the buffer with
PBS and 100 µl was applied to 101L cells grown in 500 µl of media in
24-well plates. The rat hepatoma cell line BP8 lacks functional AHR protein
(Weiss et al., 1996
).
Transient transfection of BP8 cells was achieved using Effectene Transfection
Reagent (QIAGEN, Valencia, CA). The plasmids used in the transfections were
the following: pCH110, containing the gene for
-galactosidase under
control of the SV40 early promoter (Pharmacia, Peapack, NJ); pGudLuc2.0-DRE3,
containing firefly luciferase under control of a synthetic DRE driving a
minimal promoter (a gift from Michael S. Denison, University of California,
Davis, Davis, CA); and PL1722, containing the mouse B1 allele of AHR under
control of the cytomegalovirus promoter in the parent vector pDEST12.2
(Invitrogen). Cells were grown for 24 h after transfection before the addition
of experimental compounds.
Preparation of Tissue Extracts. C57BL/6J mice were killed by cervical dislocation. The tissues were dissected under sterile conditions, minced in PBS (5 ml PBS/g of tissue), and incubated at 4°C overnight. All tissue extracts were subjected to centrifugation at 3000g for 15 min and filter-sterilized through a 0.22-µm filter. To generate large amounts of heart extract, frozen mouse hearts (Pel-Freeze, Biologicals, Rogers, AR) were briefly rinsed with PBS, minced in 40 mM HEPES, pH 7.5 (2 ml buffer/heart), and incubated at 4°C overnight. The extract was then subjected to centrifugation at 3,000g for 15 min and filtered through a 0.22-µm filter. Heart extract was concentrated using an Ultrafree-15 50-kDa molecular mass cut-off ultrafiltration device (Millipore Corporation, Bedford, MA).
Protein Purification and Identification. Solid
(NH4)2SO4 was added to the heart extract to a
final concentration of 45% saturation and stirred at 4°C for 1 h. All
subsequent purification steps occurred at room temperature. Precipitated
proteins were removed by centrifugation, and the supernatant was loaded onto a
Hi-Trap phenyl HP Sepharose column (Amersham Biosciences) preequilibrated with
55% (NH4)2SO4 in 40 mM HEPES, pH 7.5. Bound
proteins were eluted with a gradient of 55% to 0%
(NH4)2SO4 in 40 mM HEPES, pH 7.5. Fractions
containing the activity peak were desalted into 20 mM HEPES, pH 8.5, using
PD10 columns and loaded onto a HiTrap Q FF Sepharose anion exchange column
(Amersham Biosciences) that was preequilibrated with 20 mM HEPES, pH 8.5.
Bound proteins were eluted with a 0- to 500-mM NaCl gradient in 20 mM HEPES,
pH 8.5. Fractions containing activity were pooled, and the buffer was
exchanged with 25 mM diethanolamine, pH 9.5, with PD10 columns. The sample was
then loaded onto a MonoP chromatofocusing column that had been preequilibrated
with 25 mM diethanolamine, pH 9.5, and bound proteins were eluted with a pH
gradient of 9.0 to 6.0 in 10% PB96 (Amersham Biosciences). Active fractions
were pooled, concentrated with an Ultrafree-15 50-kDa molecular mass cut-off
ultrafiltration device, and loaded onto a HiPrep 16/60 Sephacryl S200 gel
filtration column (Amersham Biosciences) that had been preequilibrated with
PBS, and proteins were eluted with PBS. Protein fractions were analyzed by
SDS-PAGE and visualized with SYPRO-Ruby stain (Bio-Rad, Hercules, CA). The
major protein band in the fraction containing the activity peak was excised
from the gel and trypsinized, and the resulting peptides were analyzed by
MALDI-TOF mass spectrometry at the University of Wisconsin Biotechnology
Center (Madison, WI). Masses of the peptide fragments were used to search the
protein databases using the computer program MS-Fit (University of California,
San Francisco, San Francisco, CA) (Clauser
et al., 1999
).
Separation of I3P Derivatives. Stock solutions of 100 mM I3P in ethanol were diluted into PBS to a final concentration of 5 mM and allowed to incubate protected from light at room temperature for various periods of time. Solutions of I3P were fractionated by passage of 5 ml of 5 mM I3P in PBS over a C18 SPICE solid-phase extraction cartridge (Analtech, Newark, DE), washed with 5 ml of water, and eluted with 3 ml of methanol. Methanol elutions were concentrated by evaporation under nitrogen and dissolved in smaller volumes of methanol. Compounds in the methanol elutions were separated by HPLC onto a C18 column (Alltima C18 5 µ; Alltech Associates, Deerfield, IL) using a 5-min elution with 0.05% triethylamine in water followed by a 100-min linear gradient of 0.05% triethylamine in water to 100% methanol with a 1 ml/min flow rate. Eluted compounds were detected by monitoring the optical absorbance at 280 nm (A280). To measure inducing activity, 0.25-ml fractions were collected, and an aliquot of each fraction was added to 101L cells and assayed as described above.
CYP1A1 Inhibition Assay. Fourteen units of purified CYP1A1
microsomes (Sigma-Aldrich) were diluted in 162 µl of 25 mM
4-morpholinepropanesulfonic acid, pH 7.5/0.025% sodium azide/1 mM EGTA/10%
glycerol. Three microliters of 0.1 mM ethoxyresorufin (Sigma-Aldrich) in
ethanol and 20 µl of the various competitor compounds were added to each
reaction. Competitor compounds were diluted into PBS from 100-mM ethanol
stocks. Where necessary, I3P solutions were incubated at room temperature in
the dark for 20 h. Reactions were initiated with 20 µl of 5 mM
-nicotinamide adenine dinucleotide phosphate-reduced tetrasodium salt,
and the accumulation of the hydroxyresorufin was monitored at room temperature
in a microplate fluorometer using an excitation wavelength of 510 nm and an
emission wavelength of 590 nm.
| Results and Discussion |
|---|
|
|
|---|
|
To confirm that the factor activated transcription via the AHR, we monitored the response of a DRE-driven reporter in cells with and without the receptor. Rat BP8 cells, which lack endogenous AHR, were used as our receptor-deficient cell line, and BP8 cells that had been transiently transfected with AHR were used as our receptor-positive cell line. Cells were either exposed to 40 mM HEPES, pH 7.5, or the concentrated heart extract in HEPES buffer. For use as controls, we included 20 nM TCDD or the solvent DMSO. Expression of the luciferase reporter gene was quantified after an 18-h induction period (Fig. 1B). None of the experimental treatments induced transcription from the DRE promoter without the expression of AHR. In cells transfected with the AHR expression construct, both TCDD and the concentrated heart extract increased reporter gene activity, indicating that AHR is necessary to mediate the transcriptional response to the heart extract.
Purification and Identification of Aspartate Aminotransferase as the
Active Component. In preliminary biochemical studies of the heart extract,
a number of important observations were made that directly led to the success
of the purification strategy (data not shown). First, whenever a
high-resolution purification step was used, very little activity was
recovered. This low recovery was in contrast to our data indicating that the
activity in the heart extract was quite stable to heat, pH, and salt. This
observation suggested that multiple components of heart extract were needed in
combination for the AHR-inducing activity. Second, in various chromatographic
separations, we observed that the inducing activity always eluted in fractions
adjacent to fractions that had a deep red color. Moreover, when we combined
fractions containing the red color with fractions that had low activity, we
found that activity was increased significantly. Because this red protein was
very abundant, it was readily purified and identified by MALDI-TOF mass
spectrometry to be
-hemoglobin. This led us to add commercially
available rat hemoglobin (0.5 mg/ml, final concentration) in combination with
the column fractions when assaying for AHR-inducing activity. This addition
restored the activity of our fractions and allowed us to purify the active
component to near homogeneity.
We developed a protein-purification scheme to isolate the active component
of heart extract (Fig. 2A). We
followed the purification of the active component by performing SDS-PAGE on
active fractions from each chromatographic step. We found the active fractions
from the final gel-filtration step contained only one major protein
(Fig. 2, B and C). To identify
this protein, the protein band was excised from the gel and trypsinized, and
the resulting peptides were analyzed by MALDI-TOF mass spectrometry
(Fig. 2D). This procedure
identified this major protein as cAST (also known as aspartate transaminase or
glutamate oxaloacetate transaminase-1; EC 2.6.1.1
[EC]
). This enzyme is best known
to catalyze the transfer of an amino group from aspartate to
-ketoglutarate producing oxaloacetate and glutamate
(Fig. 2E). Two isoforms of this
aminotransferase are present in cells, one in the cytosol (cAST), and one in
the mitochondria (mAST) (Cooper and
Meister, 1985
). These enzymes are known to play a role in
gluconeogenesis and in the malate-aspartate shuttle, which transports reducing
equivalents from the cytosol to the mitochondria
(Cooper and Meister, 1985
).
Heart tissue is known to express extremely high levels of AST, and elevated
levels of AST in the serum are used as a clinical indication of cardiac damage
(Schmidt and Schmidt,
1985
).
|
To confirm that AST was the source of the activity in our heart extracts, we obtained commercially available porcine cAST and found that it activated AHR signaling in a hemoglobin-dependent manner (Fig. 3A). Although our purification only identified cAST as the active component released from heart tissue, we also tested the commercially available porcine mAST and found that this protein was just as active as cAST in our AHR reporter assay system (data not shown).
|
Exogenous Iron Greatly Enhances the Signaling Activity of cAST. To understand how hemoglobin was enhancing the AHR-activating activity, we performed a number of biochemical experiments. First, we found that other heme-containing proteins were also active, because both bovine hemoglobin and horse myoglobin activated AHR signaling with cAST (data not shown). Because these proteins share an iron-containing heme moiety, we also tested hemin and FeCl3 and found that both of these compounds activated AHR signaling with cAST (Fig. 3A). Finally, the addition of the heme product bilirubin did not increase cAST signaling, and the addition of a 10-fold excess of the iron chelator deferoxamine mesylate abolished activation by hemoglobin, hemin, and FeCl3 (data not shown). Taken together, these data suggest that it is the iron which is contained in these compounds that acts with cAST to activate AHR signaling.
The Enzymatic Activity of cAST Activates AHR. With the
identification of cAST came the initial hypothesis that one or more of the
products of its enzymatic reaction is related to the activation of AHR. To
test this, the substrates aspartate,
-ketoglutarate, oxaloacetate, and
glutamate were added to 101L cells at a final concentration of 1 mM and tested
for their ability to activate AHR in the absence of cAST. None of these
compounds induced AHR signaling when added to the cell-culture media
(Fig. 3B) and did not activate
AHR signaling when added to cells in combination with hemoglobin (data not
shown). The addition of
-ketoglutarate and oxaloacetate, the amino
group acceptor compounds, enhances the AHR signaling of cAST, whereas the
amino donor compounds aspartate and glutamate, either slightly reduce the
signaling or have no effect, respectively
(Fig. 3B). Taken together,
these data suggest that it is the enzymatic activity of cAST that is
stimulating the AHR pathway; however, aspartate and glutamate are not the
amino donor compounds.
To identify the amino donor compounds that were the source of the AHR
signaling activity, we screened each common amino acid for its ability to
activate AHR signaling in a cAST-dependent manner
(Fig. 3C). Each amino acid was
added to the cell-culture medium (0.4 mM final concentration) in combination
with 0.4 mM
-ketoglutarate and 0.2 mg/ml of rat hemoglobin. None of the
amino acids activated AHR signaling in the absence of cAST. When added to
cells with 13 U/ml porcine cAST, we consistently observed increased signaling
in treatments containing tryptophan or tyrosine, with tryptophan providing the
greatest increase in signaling. The hydroxylated derivative of tryptophan,
5-hydroxy-L-tryptophan (5-HT), was also found to activate AHR
signaling in a cAST-dependent manner, with 5-HT being nearly as active as
tryptophan when added to 101L cells in combination with cAST,
-ketoglutarate, and hemin (Fig.
3D).
Given that cAST is known to use aromatic amino acids as alternative
substrates (Miller and Litwack,
1971
; Minatogawa et al.,
1976
), we diagramed the transamination reactions using tryptophan,
tyrosine, and 5-HT as amino donor compounds
(Fig. 3E). Transamination
reactions with tryptophan, tyrosine, and 5-HT as amino donor compounds
generate I3P, HPP, and 5-hydroxyindolepyruvate, respectively
(Cooper and Meister, 1985
).
When we added 500 µM I3P or HPP to the cell-culture system, both compounds
activated AHR signaling, with I3P being much more active than HPP
(Fig. 3F). 5-Hydroxyindolepyruvate was not tested for activity because it is not
commercially available. The signaling activities of both I3P and HPP were
greatly enhanced by the addition of 100 µM FeCl3 to the cells.
Hemoglobin and hemin were also found to enhance the activity of I3P and HPP
(data not shown), suggesting that the iron requirement of cAST in our activity
assay occurs after the enzymatic reaction catalyzed by cAST. Because I3P
activated AHR signaling much more than HPP, we focused the remainder of our
studies on I3P.
I3P Spontaneously Reacts in Aqueous Solution to Form AHR Agonists.
Although stock solutions of I3P in ethanol seem relatively stable, on dilution
into PBS, I3P solutions begin to turn pink within minutes of dilution and
become red-orange after an overnight incubation at room temperature (data not
shown). In an effort to determine whether this aqueous instability was related
to AHR signaling activity, aqueous solutions of I3P were incubated for various
times at room temperature, protected from light, and screened for AHR
signaling activity. We observed a rapid increase in AHR signaling activity,
with a maximum accumulation of activity between 10 and 48 h of incubation
(Fig. 4A). When oxygen was
bubbled through aqueous solutions of I3P, we observed a more rapid
accumulation of colored products and AHR signaling activity (data not shown),
suggesting that oxidative chemical reactions are involved in generating AHR
agonists from I3P. Because the addition of FeCl3 would increase the
oxidative environment of the cell-culture media
(Ercal et al., 2001
), the
synergistic role of iron in our activity assays may be explained by an
accelerated oxidation of I3P and I3P derivatives mediated by iron. These
experiments led us to conclude that I3P is itself not active as an AHR
agonist, but that it spontaneously converts to one or more agonist compounds
in aqueous solution.
|
I3P and HPP Synergistically Interact. Although HPP has much less inducing activity than I3P, HPP synergistically interacts with I3P to activate AHR signaling. Exposure of cells to a final concentration of 12.5 µM of both I3P and HPP activated AHR signaling substantially more than did exposure to 25 µM of I3P alone in the presence of 100 µM FeCl3 (Fig. 4B). This observation suggests that I3P and HPP are either reacting together to form increased quantities of the I3P-derived agonist(s) or reacting together to generate one or more agonist compounds that are structurally distinct from the agonist(s) derived from I3P alone.
I3P Derivatives Bind the Active Site of CYP1A1. We predicted that,
like many of the polycyclic aromatic compounds that activate AHR, ligands of
the AHR would also be metabolized by the battery of XMEs that are regulated by
AHR. To determine whether I3P derivatives interact with the active site of the
CYP1A1 protein, we measured the ability of I3P derivatives to inhibit CYP1A1
enzymatic activity with the substrate ethoxyresorufin. Various amounts of
either preincubated or freshly made I3P aqueous solutions were added to
microsomes containing purified CYP1A1, and ethoxyresorufin-deethylase activity
was measured. We observed that the preincubated I3P had approximately 10-fold
greater inhibitory activity than the I3P that was diluted into PBS and assayed
immediately (Fig. 4C). The
compound indole-3-acetate, which is not an inhibitor of CYP1A1
(Heath-Pagliuso et al., 1998
),
was included as a negative control. We plotted CYP1A1 kinetic data in a
Lineweaver-Burk plot to determine the nature of this competitive interaction
(Fig. 4D). This analysis led us
to conclude that the I3P derivatives act as a "mixed competitor"
in our assays, suggesting that the binding of I3P derivatives occurs at enzyme
sites involved in both substrate binding and catalysis. Thus, the compounds
generated from I3P not only induce transcription of the CYP1A1 gene
via AHR activation, they also bind to the active site of the CYP1A1 protein as
well. This is consistent with our hypothesis that these compounds may act as
endogenous agonists of AHR and induce their own metabolism.
Multiple Agonist Compounds Are Generated from I3P. To determine the number of biologically active products that were produced from I3P, we separated the aqueous reaction products by solid-phase extraction onto C18 resin. This separation generated three crude fractions: compounds that did not bind the C18 resin, compounds that eluted with water, and compounds that eluted with methanol. Aliquots of each of these fractions were added to 101L cells to determine which fraction contained the most activity (Fig. 5A). When solutions of I3P that were incubated for 20 h were separated, large amounts of activity were observed in all three fractions. These results indicate that the activity generated during the incubation is caused not by the formation of a single I3P derivative with agonist activity but by multiple compounds with a wide range of hydrophobic character.
|
In an effort to determine the complexity of the I3P derivatives that
activate AHR signaling, we resolved the more hydrophobic derivatives of I3P
that eluted from the C18 resin with methanol. We separated the compounds in
this mixture by reverse-phase HPLC and assayed each fraction in our
cell-culture system. We compared HPLC profiles of the compounds from aqueous
solutions of I3P that were incubated at room temperature for 20 h as well as
solutions of I3P that were subjected to solid-phase extraction immediately
after dilution into PBS, designated time 0 h. The HPLC profile of the
compounds in the 0-h incubation demonstrates that derivatives of I3P are
beginning to form even in the short period during which I3P is exposed to an
aqueous environment (Fig. 5B).
However, these early products had little AHR signaling activity
(Fig. 5C). The major product in
this mixture was identified as indole-3-carboxaldehyde (data not shown), which
is known not to be an agonist of the AHR
(Bradfield and Bjeldanes,
1987
). The HPLC profile of the products of the 20-h incubation
indicated that I3P converts to dozens of distinct compounds
(Fig. 5D). What was striking
about the activity profile of column fractions from the 20-h products was the
large number of peaks of activity. The activity profile was almost as complex
as the A280 trace (Fig.
5E), indicating that a large number of I3P derivatives are AHR
agonists. As a control to ensure that our HPLC analysis and assay system was
not responsible for the complex profile, we separated a stock solution of BNF
on the column and observed a single major A280 and
activity peak (data not shown).
| Conclusions |
|---|
|
|
|---|
A number of previous reports have shown that tryptophan derivatives can
activate AHR signaling (Rannug et al.,
1987
; Helferich and Denison,
1991
; Miller,
1997
; Heath-Pagliuso et al.,
1998
; Wei et al.,
2000
). In fact, it has been suggested that an unknown
tryptophan-derived endogenous ligand is generated in mouse Hepa-1 cell lines,
which both induces CYP1A1 transcription and is metabolized by the
CYP1A1 protein (Wei et al.,
2000
). We demonstrate in this study that the known tryptophan
metabolite I3P spontaneously reacts to form a family of AHR agonist compounds
and that at least some of the I3P derivatives interact with the active site of
the CYP1A1 protein. As an analogy to the concept of a procarcinogen from the
field of chemical carcinogenesis, we refer to I3P as a
"proagonist" compound because I3P does not activate AHR itself,
but it is derivatives of I3P that activate AHR.
Although the structural determination of the ultimate agonist compounds
derived from these proagonists will be an important achievement, it will be a
time-consuming undertaking. Because I3P has the potential to react with other
compounds within the cell, our identification of the most hydrophobic AHR
agonists derived solely from I3P (Fig.
5E) is probably an underestimate of the complexity of compounds
that can act as endogenous agonists of AHR. For example, the synergistic
interaction of I3P and HPP in the activation of AHR signaling may be caused by
the formation of a different spectrum of AHR agonist compounds beyond those
generated from I3P alone. In addition, because
5-hydroxy-L-tryptophan activates AHR in combination with AST, we
predict that the proagonist 5-hydroxyindolepyruvate is generated, and it is
likely that at least some of the AHR agonists generated from this compound are
different from those generated from I3P. Interestingly, a product of I3P and
cysteine may have already been identified from lung tissue
(Song et al., 2002
). Taken
together, these data support the proposal that there is no single endogenous
ligand of AHR, but that the AHR has evolved to respond to many different
hydrophobic by-products of normal metabolism
(Denison et al., 2002
).
These results also highlight issues relevant to clinical pharmacology. For
example, I3P has recently been used in a variety of clinical trials to reduce
anxiety and induce sleep, with doses as large as 300 mg administered orally to
volunteers (Politi et al.,
1999
). Because we found acidified solutions of I3P to generate
agonist activity much more rapidly than solutions of I3P at neutral pH (data
not shown), oral administration of I3P would expose I3P to the acidic stomach
environment and would introduce a great potential of generating potent AHR
agonists within the gastrointestinal tract. Exposure to such AHR agonists may
unexpectedly alter drug metabolism in I3P recipients via the induction of the
xenobiotic-metabolizing enzyme battery. In fact, because exposure to AHR
agonists has been shown to increase serum tryptophan levels
(Unkila et al., 1998
), it is
possible that some of the pharmacological effects of the I3P administration
may be ultimately attributed to the AHR agonists generated from I3P.
| Acknowledgements |
|---|
| Footnotes |
|---|
ABBREVIATIONS: AHR, aryl hydrocarbon receptor; ARNT, aryl
hydrocarbon receptor nuclear translocator; DRE, dioxin response element; PBS,
phosphate-buffered saline; XME, xenobiotic-metabolizing enzymes; BNF,
-naphthoflavone; DMSO, dimethyl sulfoxide; cAST, cytosolic aspartate
aminotransferase; I3P, indole-3-pyruvate; HPP, 4-hydroxyphenylpyruvate; 5-HT,
5-hydroxy-L-tryptophan; PAGE, polyacrylamide gel electrophoresis;
AST, aspartate aminotransferase; mAST, mitochondrial aspartate
aminotransferase; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; HPLC,
high-performance liquid chromatography.
Address correspondence to: Christopher A. Bradfield, Ph.D., McArdle Laboratory for Cancer Research, 1400 University Avenue, Madison, WI 53706. E-mail: bradfield{at}oncology.wisc.edu
| References |
|---|
|
|
|---|
Bradfield CA and Bjeldanes LF (1987) Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health 21: 311323.[Medline]
Clauser KR, Baker P, and Burlingame AL (1999) Role of accurate mass measurement (+/10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem 71: 28712882.[Medline]
Cooper AJL and Meister A, editors (1985) Metabolic Significance of Transamination. John Wiley & Sons, New York.
Denison MS, Pandini A, Nagy SR, Baldwin EP, and Bonati L (2002) Ligand binding and activation of the Ah receptor. Chem Biol Interact 141: 324.[CrossRef][Medline]
Ercal N, Gurer-Orhan H, and Aykin-Burns N (2001) Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem 1: 529539.[CrossRef][Medline]
Grose KR and Bjeldanes LF (1992) Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 5: 188193.[CrossRef][Medline]
Gu YZ, Hogenesch J, and Bradfield C (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40: 519561.[CrossRef][Medline]
Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307340.[CrossRef][Medline]
Heath-Pagliuso S, Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A, and Denison MS (1998) Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37: 1150811515.[CrossRef][Medline]
Helferich WG and Denison MS (1991) Ultraviolet photoproducts of tryptophan can act as dioxin agonists. Mol Pharmacol 40: 674678.[Abstract]
Lahvis G, Lindell S, Thomas R, McCuskey R, Murphy C, Glover E,
Bentz M, Southard J, and Bradfield C (2000) Portosystemic shunts
and persistent fetal vascular structures in Ah-receptor deficient mice.
Proc Natl Acad Sci USA
97:
1044210447.
McDonnell WM, Chensue SW, Askari FK, Moseley RH, Fernandez-Salguero P, Gonzalez FJ, and Ward JM (1996) Hepatic fibrosis in Ahr/mice. Science (Wash DC) 271: 223224.[Medline]
Miller CA 3rd (1997) Expression of the human aryl
hydrocarbon receptor complex in yeast. Activation of transcription by indole
compounds. J Biol Chem
272:
3282432829.
Miller JE and Litwack G (1971) Purification,
properties and identity of liver mitochondrial tyrosine aminotransferase.
J Biol Chem 246:
32343240.
Minatogawa Y, Noguchi T, and Kido R (1976) Purification, characterization and identification of tryptophan aminotransferase from rat brain. J Neurochem 27: 10971101.[CrossRef][Medline]
Nebert DW, Goujon FM, and Gielen JE (1972) Aryl hydrocarbon hydroxylase induction by polycyclic hydrocarbons: simple autosomal dominant trait in the mouse. Nat New Biol 236: 107110.[Medline]
Poland A, Knutson J, and Glover E (1985) Studies on the mechanism of action of halogenated aromatic hydrocarbons. Clin Physiol Biochem 3: 147154.[Medline]
Politi V, De Luca G, Gallai V, Puca, and Comin M (1999) Clinical experiences with the use of indole-3-pyruvic acid. Adv Exp Med Biol 467: 227232.[Medline]
Postlind H, Vu TP, Tukey RH, and Quattrochi LC (1993) Response of human CYP1-luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 118: 255262.[CrossRef][Medline]
Rannug A, Rannug U, Rosenkranz HS, Winqvist L, Westerholm R,
Agurell E, and Grafstrom AK (1987) Certain photooxidized
derivatives of tryptophan bind with very high affinity to the Ah receptor and
are likely to be endogenous signal substances. J Biol
Chem 262:
1542215427.
Safe S, Bandiera S, Sawyer T, Robertson L, Safe L, Parkinson A, Thomas PE, Ryan DE, Reik LM, Levin W, et al. (1985) PCBs: structure-function relationships and mechanism of action. Environ Health Perspect 60: 4756.[Medline]
Sawyer T and Safe S (1982) PCB isomers and congeners: induction of aryl hydrocarbon hydroxylase and ethoxyresorufin O-deethylase enzyme activities in rat hepatoma cells. Toxicol Lett 13: 8793.[CrossRef][Medline]
Schmidt E and Schmidt FW, editors (1985) Aminotransferases in Human Pathology and Clinical Chemistry. John Wiley & Sons, New York.
Schmidt JV and Bradfield CA (1996) Ah receptor signaling pathways. Annu Rev Cell Dev Biol 12: 5589.[CrossRef][Medline]
Schmidt JV, Su GH, Reddy JK, Simon MC, and Bradfield CA
(1996) Characterization of a murine Ahr null allele: involvement
of the Ah receptor in hepatic growth and development. Proc Natl
Acad Sci USA 93:
67316736.
Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski
RR, and DeLuca HF (2002) A ligand for the aryl hydrocarbon
receptor isolated from lung. Proc Natl Acad Sci USA
99:
1469414699.
Unkila M, Pohjanvirta R, and Tuomisto J (1998) Body weight loss and changes in tryptophan homeostasis by chlorinated dibenzo-p-dioxin congeners in the most TCDD-susceptible and the most TCDD-resistant rat strain. Arch Toxicol 72: 769776.[CrossRef][Medline]
Wei YD, Bergander L, Rannug U, and Rannug A (2000) Regulation of CYP1A1 transcription via the metabolism of the tryptophan-derived 6-formylindolo[3,2-b]carbazole. Arch Biochem Biophys 383: 99107.[CrossRef][Medline]
Weiss C, Kolluri SK, Kiefer F, and Gottlicher M (1996) Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 226: 154163.[CrossRef][Medline]
Whitlock JP Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39: 103125.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
I. Teneng, V. Stribinskis, and K. S. Ramos Context-specific regulation of LINE-1 Genes Cells, October 1, 2007; 12(10): 1101 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. McMillan and C. A. Bradfield The Aryl Hydrocarbon Receptor sans Xenobiotics: Endogenous Function in Genetic Model Systems Mol. Pharmacol., September 1, 2007; 72(3): 487 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Okey An Aryl Hydrocarbon Receptor Odyssey to the Shores of Toxicology: The Deichmann Lecture, International Congress of Toxicology-XI Toxicol. Sci., July 1, 2007; 98(1): 5 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn Genomic Profiling in Nuclear Receptor-Mediated Toxicity Toxicol Pathol, June 1, 2007; 35(4): 474 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hu, C. Sorrentino, M. S. Denison, K. Kolaja, and M. R. Fielden Induction of Cyp1a1 Is a Nonspecific Biomarker of Aryl Hydrocarbon Receptor Activation: Results of Large Scale Screening of Pharmaceuticals and Toxicants in Vivo and in Vitro Mol. Pharmacol., June 1, 2007; 71(6): 1475 - 1486. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Diani-Moore, E. Labitzke, R. Brown, A. Garvin, L. Wong, and A. B. Rifkind Sunlight Generates Multiple Tryptophan Photoproducts Eliciting High Efficacy CYP1A Induction in Chick Hepatocytes and In Vivo Toxicol. Sci., March 1, 2006; 90(1): 96 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mulero-Navarro, E. Pozo-Guisado, P. A. Perez-Mancera, A. Alvarez-Barrientos, I. Catalina-Fernandez, E. Hernandez-Nieto, J. Saenz-Santamaria, N. Martinez, J. M. Rojas, I. Sanchez-Garcia, et al. Immortalized Mouse Mammary Fibroblasts Lacking Dioxin Receptor Have Impaired Tumorigenicity in a Subcutaneous Mouse Xenograft Model J. Biol. Chem., August 5, 2005; 280(31): 28731 - 28741. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||